Rights Contact Login For More Details
- Wiley
More About This Title Antiplatelet Therapy in Cardiovascular Disease
English
This important new book:
- Begins with a concise but thorough discussion of platelet biology and pathophysiology so that readers understand how these therapies work and why they can also produce such a varied range of complications, from minor gastrointestinal upset, to potentially life-threatening conditions such as neutropenia, a critical shortage of white blood cells.
- Thoroughly covers platelet function testing, including new, novel techniques.
- Clarifies current best-practices regarding the use of antiplatelet agents in both chronic and acute cardiovascular disease
- Reviews of all types of antiplatelet agents – from aspirin to recently approved drugs – including indications, clinical outcomes, and side effects/complications
Written by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.
English
Ron Waksman, MD, FACC, is Associate Director, Division of Cardiology and Director of Experimental Angioplasty & New Technologies, Washington Hospital Center, Washington, DC. Dr. Waksman is currently the Editor-in-Chief of Cardiovascular Revascularization Medicine and sits on the editorial boards of six other internationally published journals. He has been Editor/Co-Editor of six books since 1996 and has authored 22 additional book chapters. Dr. Waksman has also authored/co-authored over 250 published manuscripts and over 200 abstracts. He is also a Clinical Professor of Medicine (Cardiology) at Georgetown University, Washington, DC, USA.
English
List of Contributors, viii
Foreword, xix
Preface, xxi
Section I: Platelet biology and pathophysiology
1 Platelet Pathophysiology and its Role in Thrombosis, 3
Paul A. Gurbel and Udaya S. Tantry
2 Platelet Receptors and Drug Targets: COX-1, 8
Thomas Hohlfeld and Karsten Schror
3 Platelet Receptors and Drug Targets: P2Y12, 14
Marco Cattaneo
4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21
Eliano Pio Navarese and Jacek Kubica
5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29
Ping Zhang, Lidija Covic, and Athan Kuliopulos
6 Role of Inflammation and Hypercoagulability in Thrombosis, 45
Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry
Section II: Platelet function tests
7 Light Transmission Aggregometry, 53
Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry
8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58
Marc Laine, Franck Paganelli, and Laurent Bonello
9 VerifyNow P2Y12 and Plateletworks Assays, 65
Matthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg
10 Multiplate Analyzer, 82
Martin Orban and Dirk Sibbing
11 Shear Stress-Based Platelet Function Tests, 92
Nicoline J. Breet and Jurriën M. ten Berg
12 Thrombelastography and Other Novel Techniques, 102
Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel
Section III: Antiplatelet pharmacology
13 Aspirin, 111
Karsten Schrör and Thomas Hohlfeld
14 Cilostazol, 117
Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park
15 Abciximab, 125
J. Emilio Exaire and Jorge F. Saucedo
16 Tirofiban, 131
Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm
17 Eptifibatide, 142
Nevin C. Baker and Ron Waksman
18 Ticlopidine, 150
Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano, and Dominick J. Angiolillo
19 Clopidogrel, 160
Andrzej Budaj
20 Prasugrel, 166
Christoph Varenhorst, Anna Oskarsson, and Stefan James
21 Elinogrel, 173
Matthew J. Chung and Sunil V. Rao
22 Cangrelor, 180
Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, and Dominick J. Angiolillo
23 Ticagrelor, 193
Anna Oskarsson, Christoph Varenhorst, and Stefan James
24 Thrombin Receptor Antagonists, 198
Flavio de Souza Brito and Pierluigi Tricoci
Section IV: Percutaneous Coronary Intervention and Antiplatelet Therapy
25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209
Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio
26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220
Joshua P. Loh and Ron Waksman
27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229
Michael A. Gaglia, Jr. and Ray V. Matthews
28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237
Ana Laynez and Ron Waksman
29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245
Aung Myat, Yousif Ahmad, and Simon R. Redwood
30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253
Sa'ar Minha and Ron Waksman
31 Bleeding Definitions, 259
Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran
Section V: Antiplatelet Responsiveness
32 Personalizing Antiplatelet Therapy, 269
Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry
33 Aspirin Resistance, 277
Muthiah Vaduganathan and Eli I. Lev
34 Clopidogrel Resistance, 285
Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel
35 Genetics of Clopidogrel Poor Response, 293
Pierre Fontana and Jean-Luc Reny
36 Proton Pump Inhibitors and Clopidogrel, 300
Michael A. Gaglia, Jr
37 Other Drug Interactions with Clopidogrel, 306
Eric R. Bates
Index, 314
English
“Written by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.” (Kingbook73's Medical Ebook and Video Collection, 20 August 2014)
